Market Research Future published a research report on Global Peptic Ulcer Drugs Market - Forecast To 2022 Report gives a clear picture of current market scenario which includes past and estimated future market size. The report provides detail information and strategies of top key players in the industry. The report also gives a broad study about different markets segments and regions.
Peptic Ulcer Drugs Market Overview
Advancement in technology is aiding the pharmaceutical sector for development of highly effective drugs that are used for treating multiple disorders. Peptic ulcer drugs are used to treat the ulcer caused due to imbalance between defensive and aggressive fluids in the stomach. Market Research Future (MRFR) has published a report stating that the global peptic ulcer drugs market is marked to expand at a moderate CAGR of 3.8% during 2016-2022 and reach the valuation of USD 36.27 Bn by the end of 2022 from USD 29 Bn in 2015.
The global peptic ulcer drugs market is segmented on the basis of pharmacological class and clinical application. Based on pharmacological class, the global peptic ulcer drugs market has been segmented into proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others. With respect to market valuation, the proton pump inhibitors (PPIs) segment is anticipated to project dominance over the global peptic ulcer drugs market during the forecast period. Based on clinical application, the global peptic ulcer drugs market has been segmented into gastric ulcers, duodenal ulcers and esophageal ulcer.
Geographically, the global peptic ulcer drugs market has been segmented into four major regions such as North America, Asia Pacific, Europe, and the Middle East and Africa. The North America region is projected to be the largest market for peptic ulcer drugs owing to the rapid adoption of advanced technology and automation of processes for drug manufacturing in pharmaceutical industry and increasing prevalence of ulcer and other intestinal disorders as a result of changing lifestyle and unhealthy food habits in this region. The peptic ulcer drugs market in the Europe region is projecting to expand at a significant growth rate during the forecast period owing to the increased research activities for the development of more effective drugs to cure peptic ulcers.
The Asia Pacific region is anticipated to expand at the fastest growth rate in the global peptic ulcer drugs market owing to the increasing demand for high-quality drugs to cure intestinal disorders and rapid development of healthcare sector in the emerging economies of this region. The Middle East and Africa region is projecting steady growth in the global peptic ulcer drugs market owing to the lack of awareness and poor healthcare facilities in the underdeveloped areas of this region.
GET Global Peptic Ulcer Drugs Market Information, by Pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by Clinical Application (gastric ulcers, duodenal ulcer, esophageal ulcer) - Forecast Till 2022 @ https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445
The key players profiled by MRFR that are operating in the global peptic ulcer drugs market are Novartis AG, Daiichi Sankyo Company Limited, Actelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals
Related Latest Trending Reports
Bone Densitometers Market Research Report- Forecast to 2022
Population Health Management Market Research Report- Global Forecast To 2023
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.